The Esophageal Cancer Action Network, or ECAN, is working to shine light on the possibility of over-the-counter acid reflux medications increasing a patient’s risk for a type of cancer called Barrett’s esophagus. The group recently conducted a poll that found 86 percent of Americans are unaware of the danger they assume when taking common drugs like Prilosec and Nexium.
The problem may lie with ...
continue reading...
Known as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.
Unfortunately, this relatively new class of drugs has already allegedly caused enough ...
continue reading...
Pharmaceutical giant AstraZeneca has been given the go-ahead to market a new, 60-milligram dose of their blood thinner Brilinta for longer-term use in patients who have suffered heart attacks. According to Reuters, the U.S. Food and Drug Administration (FDA) approved the new dose for use along with aspirin at any time after a heart attack. Brilinta, an antiplatelet drug used to prevent blood clots, was previously available only at a higher dosage, and ...
The FDA is recommending that the pharmaceutical giant AstraZeneca include information about increased risk of heart failure on the label of its diabetes drug Onglyza.
An FDA advisory panel met on April 14 to discuss data linking AstraZeneca’s Onglyza, as well as Takeda’s diabetes drug, Nesina, to increased risk of hospitalization due to heart failure. According to Bloomberg, 14 of 15 panel members voted in favor of recommending that AstraZeneca ...
continue reading...A new FDA report has concluded that AstraZeneca’s new diabetes drug Onglyza may be associated with an increased risk of death, Reuters reports.
This is not the first time AstraZeneca has come under scrutiny for its anti-diabetic drugs. As early as 2008, the FDA began receiving reports of hemorrhagic and necrotizing pancreatitis developing in patients taking AstraZeneca’s incretin mimetic drug Byetta, used ...
continue reading...
The results of AstraZeneca’s recent trials for its blood-thinning drug Brilinta show a decreased risk of post–heart attack heart problems but an increased risk of major bleeding after using the drug. The pharmaceutical company’s large-scale PEGASUS-TIMI 54 trial included 21,000 patients who had suffered at least one heart attack in the past three years. Patients received either a high dose of Brilinta, a low dose of Brilinta, or a placebo drug. All patients ...
